2000/02/01 by Rafael de la Torre, Magı́ Farré, Jordi Ortuño +8 · 6 citations
Business, Management and Accounting · Health Professions · Medicine · Pharmacology, Toxicology and Pharmaceutics · Psychology · #Cannabis and Cannabinoid Research #Electronic Health Records Systems #Forensic Toxicology and Drug Analysis #Healthcare Systems and Technology #Psychedelics and Drug Studies
paper · pdf · doi:10.1046/j.1365-2125.2000.00121.x
openalex publication_date 2009/03/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/02
It has previously been postulated that individuals genetically deficient for the hepatic enzyme CYP2D6 (about 10% of the Caucasian people) were at risk of developing acute toxicity at moderate doses of MDMA because the drug would accumulate in the body instead of being metabolized and inactivated. The lack of linearity of MDMA pharmacokinetics (in a window of doses compatible with its recreational use) is a more general phenomenon as it concerns the whole population independent of their CYP2D6 genotype. It implies that relatively small increases in the dose of MDMA ingested are translated to disproportionate rises in MDMA plasma concentrations and hence subjects are more prone to develop acute toxicity.